Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor

Clinical Infectious Diseases

Volumn 37, Issue 8, 2003, Pages 1102-1106

  Cervia, Joseph S ^a,b   Smith, Miriam A ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b Div of Infect Disease Staff House   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HYBRID PROTEIN; SYNTHETIC PEPTIDE; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DAILY LIFE ACTIVITY; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; INJECTION SITE; LIFE EXPECTANCY; LONG TERM EXPOSURE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THERAPY RESISTANCE; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; PEPTIDE FRAGMENTS;

EID: 0142187273     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378302     Document Type: Review

References (24)

1. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp 41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp 120 interactions with the coreceptor. J Virol 2001; 75:8605-14.
2. Jiang S, Zhao Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002; 8:563-80.
3. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99:16249-54.
4. Lambert DM, Barney S, Lambert AL, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 1996; 93:2186-91.
5. Xu L, Hue S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naïve and -experienced patients. AIDS 2002; 16:1684-6.
6. Ketas TJ, Frank I, Klasse PJ, et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol 2003; 77:2762-7.
7. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp 120. J Virol 2000; 74:8358-67.
8. Poveda E, Rodes B, Toro C, et al. Evolution of the gp 41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002; 16:1959-61.
9. Laurence J. T-20: a model for novel anti-HIV drugs in development. AIDS Reader 2002; 12:469-70.
10. DeClercq E. New developments in anti-HIV chemotherapy. Biochem Biophys Acta 2002; 1587:258-75.
11. DeClerq E. New anti-HIV agents and targets. Med Res Rev 2002; 22: 531-65.
12. Tremblay CL, Kollmann C, Giguel F, et al. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000; 25:99-102.
13. Tremblay CL, Giguel F, Kollmann C, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46:1336-9.
14. Nagashima KA, Thompson DAD, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potentially synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183:1121-5.
15. Hanna SL, Yang C, Owen SM, Lal RB. Resistance mutation in HIV entry inhibitors. AIDS 2002; 16:1603-8.
16. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp 41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18:685-93.
17. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication humans by T-20, a peptide inhibitor of gp 41-mediated virus entry. Nat Med 1998; 4:1232-3.
18. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
19. Clotet B, Lazzarin A, Cooper D, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals in Europe and Australia (TORO 2) [poster LbOr19A]. In: Proceedings of the 14th International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
20. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2002; 21:653-9.
21. Cohen CJ, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002; 16:327-35.
22. Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opin Investig Drugs 2002; 11:1837-43.
23. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905.
24. Mirales GD, Lalezari J, Bellos N, et al. T-1249 demonstrates potent antiviral activity over 10-day dosing in most patients who have failed a regimen containing enfuvirtide (ENF): planned interim analysis of T-1249-102, a phase I/II study [abstract 141b]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.